Prognostic Factors, Treatment, and Survival in Cutaneous Pleomorphic Sarcoma

Publication date: Available online 8 November 2018

Source: Journal of the American Academy of Dermatology

Author(s): Maria A. Ibanez, Kyle Rismiller, Thomas Knackstedt

Abstract

Background

Limited information exists on the influence of demographics, tumor characteristics, and treatment on survival in cutaneous pleomorphic sarcoma (CPS).

Objective

To describe incidence rates and prognostic factors affecting survival in CPS.

Methods

National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) data (1972-2013) was analyzed for 2423 patients diagnosed with CPS.

Results

Age-adjusted incidence rate was 0.152 cases per 100,000 person-years and was 4.5-fold higher in males than females. Male gender, white race, and increasing age over 40 were significantly associated with decreased overall survival. Head and neck tumors, tumors over 15mm, and with grade III or IV histology had significantly decreased survival. Surgical excision had a survival benefit compared no treatment. Radiation therapy did not provide a survival benefit. Patients with localized disease had the greatest survival followed by regional and distant disease.

Limitations

SEER data may not be reflective of all CPS patients. Recurrences, restaging, or additional non-mortality events over time are not tracked.

Conclusions

and Relevance: Tumor size, grade, gender, age at diagnosis, and race appear to influence survival as prognostic factors in CPS. Surgical tumor extirpation provides a survival benefit over no treatment whereas primary or adjuvant radiation does not provide a survival benefit.

https://ift.tt/2qCgm5y